Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients

Stefan K. Barta, Xiaonan (Nan) Xue, Dan Wang, Roni Tamari, Jeannette Y. Lee, Nicolas Mounier, Lawrence D. Kaplan, Josep Maria Ribera, Michele Spina, Umberto Tirelli, Rudolf Weiss, Lionel Galicier, Francois Boue, Wyndham H. Wilson, Christoph Wyen, Albert Oriol, José Tomás Navarro, Kieron Dunleavy, Richard F. Little, Lee RatnerOlga Garcia, Mireia Morgades, Scot C. Remick, Ariela Noy, Joseph A. Sparano

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P <.001), improved PFS (hazard ratio [HR] 0.50; P <.001), and OS (HR 0.51; P <.0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P <.04), PFS (ACVBP: HR 0.72; P 5.049; "intensive regimens": HR 0.35; P <.001) and OS ("intensive regimens": HR 0.54; P <.001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P 5.03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P 5.005) and trended toward improved OS (HR 0.78; P 5.07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable.

Original languageEnglish (US)
Pages (from-to)3251-3262
Number of pages12
JournalBlood
Volume122
Issue number19
DOIs
StatePublished - Nov 7 2013

Fingerprint

Non-Hodgkin's Lymphoma
Hazards
HIV
Survival
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Odds Ratio
Vincristine
Prednisone
Vindesine
Therapeutics
Lymphoma, Large B-Cell, Diffuse
Bleomycin
Etoposide
Prednisolone
Chemotherapy
Clinical Trials
Drug Therapy
Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas : A pooled analysis of 1546 patients. / Barta, Stefan K.; Xue, Xiaonan (Nan); Wang, Dan; Tamari, Roni; Lee, Jeannette Y.; Mounier, Nicolas; Kaplan, Lawrence D.; Ribera, Josep Maria; Spina, Michele; Tirelli, Umberto; Weiss, Rudolf; Galicier, Lionel; Boue, Francois; Wilson, Wyndham H.; Wyen, Christoph; Oriol, Albert; Navarro, José Tomás; Dunleavy, Kieron; Little, Richard F.; Ratner, Lee; Garcia, Olga; Morgades, Mireia; Remick, Scot C.; Noy, Ariela; Sparano, Joseph A.

In: Blood, Vol. 122, No. 19, 07.11.2013, p. 3251-3262.

Research output: Contribution to journalArticle

Barta, SK, Xue, XN, Wang, D, Tamari, R, Lee, JY, Mounier, N, Kaplan, LD, Ribera, JM, Spina, M, Tirelli, U, Weiss, R, Galicier, L, Boue, F, Wilson, WH, Wyen, C, Oriol, A, Navarro, JT, Dunleavy, K, Little, RF, Ratner, L, Garcia, O, Morgades, M, Remick, SC, Noy, A & Sparano, JA 2013, 'Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients', Blood, vol. 122, no. 19, pp. 3251-3262. https://doi.org/10.1182/blood-2013-04-498964
Barta, Stefan K. ; Xue, Xiaonan (Nan) ; Wang, Dan ; Tamari, Roni ; Lee, Jeannette Y. ; Mounier, Nicolas ; Kaplan, Lawrence D. ; Ribera, Josep Maria ; Spina, Michele ; Tirelli, Umberto ; Weiss, Rudolf ; Galicier, Lionel ; Boue, Francois ; Wilson, Wyndham H. ; Wyen, Christoph ; Oriol, Albert ; Navarro, José Tomás ; Dunleavy, Kieron ; Little, Richard F. ; Ratner, Lee ; Garcia, Olga ; Morgades, Mireia ; Remick, Scot C. ; Noy, Ariela ; Sparano, Joseph A. / Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas : A pooled analysis of 1546 patients. In: Blood. 2013 ; Vol. 122, No. 19. pp. 3251-3262.
@article{04122dfca7bf4aa4a4c8e3d13fcf466b,
title = "Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients",
abstract = "Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P <.001), improved PFS (hazard ratio [HR] 0.50; P <.001), and OS (HR 0.51; P <.0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P <.04), PFS (ACVBP: HR 0.72; P 5.049; {"}intensive regimens{"}: HR 0.35; P <.001) and OS ({"}intensive regimens{"}: HR 0.54; P <.001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P 5.03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P 5.005) and trended toward improved OS (HR 0.78; P 5.07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable.",
author = "Barta, {Stefan K.} and Xue, {Xiaonan (Nan)} and Dan Wang and Roni Tamari and Lee, {Jeannette Y.} and Nicolas Mounier and Kaplan, {Lawrence D.} and Ribera, {Josep Maria} and Michele Spina and Umberto Tirelli and Rudolf Weiss and Lionel Galicier and Francois Boue and Wilson, {Wyndham H.} and Christoph Wyen and Albert Oriol and Navarro, {Jos{\'e} Tom{\'a}s} and Kieron Dunleavy and Little, {Richard F.} and Lee Ratner and Olga Garcia and Mireia Morgades and Remick, {Scot C.} and Ariela Noy and Sparano, {Joseph A.}",
year = "2013",
month = "11",
day = "7",
doi = "10.1182/blood-2013-04-498964",
language = "English (US)",
volume = "122",
pages = "3251--3262",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas

T2 - A pooled analysis of 1546 patients

AU - Barta, Stefan K.

AU - Xue, Xiaonan (Nan)

AU - Wang, Dan

AU - Tamari, Roni

AU - Lee, Jeannette Y.

AU - Mounier, Nicolas

AU - Kaplan, Lawrence D.

AU - Ribera, Josep Maria

AU - Spina, Michele

AU - Tirelli, Umberto

AU - Weiss, Rudolf

AU - Galicier, Lionel

AU - Boue, Francois

AU - Wilson, Wyndham H.

AU - Wyen, Christoph

AU - Oriol, Albert

AU - Navarro, José Tomás

AU - Dunleavy, Kieron

AU - Little, Richard F.

AU - Ratner, Lee

AU - Garcia, Olga

AU - Morgades, Mireia

AU - Remick, Scot C.

AU - Noy, Ariela

AU - Sparano, Joseph A.

PY - 2013/11/7

Y1 - 2013/11/7

N2 - Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P <.001), improved PFS (hazard ratio [HR] 0.50; P <.001), and OS (HR 0.51; P <.0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P <.04), PFS (ACVBP: HR 0.72; P 5.049; "intensive regimens": HR 0.35; P <.001) and OS ("intensive regimens": HR 0.54; P <.001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P 5.03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P 5.005) and trended toward improved OS (HR 0.78; P 5.07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable.

AB - Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P <.001), improved PFS (hazard ratio [HR] 0.50; P <.001), and OS (HR 0.51; P <.0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P <.04), PFS (ACVBP: HR 0.72; P 5.049; "intensive regimens": HR 0.35; P <.001) and OS ("intensive regimens": HR 0.54; P <.001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P 5.03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P 5.005) and trended toward improved OS (HR 0.78; P 5.07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable.

UR - http://www.scopus.com/inward/record.url?scp=84888214986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888214986&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-04-498964

DO - 10.1182/blood-2013-04-498964

M3 - Article

C2 - 24014242

AN - SCOPUS:84888214986

VL - 122

SP - 3251

EP - 3262

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -